| Literature DB >> 35610662 |
Elisabeth Mogard1, Ann Bremander2,3,4,5, Emma Haglund2,3,6.
Abstract
BACKGROUND: There is increasing knowledge of how individual lifestyle factors affect patients with spondyloarthritis, while studies exploring the combination of unhealthy lifestyle factors are lacking. Thus, our aim was to study the frequency of two or more unhealthy lifestyle factors and their associations with physical and mental health in patients with spondyloarthritis (SpA).Entities:
Keywords: Ankylosing spondylitis; Body mass index; Health-related quality of life; Overweight/obesity; Physical activity; Psoriatic arthritis; Smoking; Spondyloarthropathy; Tobacco
Year: 2022 PMID: 35610662 PMCID: PMC9131533 DOI: 10.1186/s41927-022-00260-4
Source DB: PubMed Journal: BMC Rheumatol ISSN: 2520-1026
Characteristics of patients in each SpA subgroup and for women and men (n = 1426)
| SpA subgroup | All | Women | Men |
|---|---|---|---|
| Age, years | 57.5 (13.3) | 56.0 (13.8) | 58.4 (12.8) |
| Symptom duration, years | 28.7 (13.7) | 25.2 (13.7) | 31.0 (13.3) |
| EQ-5D (0–1)a | 0.68 (0.26) | 0.64 (0.27) | 0.70 (0.25) |
| BASDAI (0–10) | 3.6 (2.2) | 4.2 (2.2) | 3.2 (2.2) |
| BASFI (0–10) | 3.2 (2.6) | 3.5 (2.6) | 3.0 (2.5) |
| Pain (0–10) | 3.9 (2.5) | 4.3 (2.4) | 3.5 (2.5) |
| Fatigue (0–10) | 4.6 (2.7) | 5.4 (2.6) | 4.1 (2.6) |
| HADs, anxiety (0–21) | 5.5 (4.3) | 6.1 (4.4) | 5.2 (4.2) |
| HADs, depression (0–21) | 4.1 (3.4) | 3.9 (3.2) | 4.2 (3.5) |
| HEPA yes/no, n (%) | 226/207 (52/48) | 74/101 (42/58) | 152/106 (59/41) |
| BMI (kg/m2) | 25.9 (3.7) | 25.1 (3.9) | 26.4 (3.5) |
| Smoking no/stopped/yes, n (%) | 203/182/48 (47/42/11) | 84/67/24 (48/38/14) | 119/115/24 (46/45/9) |
| Snuff/snus no/stopped/yes, n (%) | 336/45/46 (78/10/11) | 161/5/5 (92/3/3) | 175/40/41 (68/16/16) |
| Age, years | 59.7 (12.4) | 58.8 (12.8) | 60.9 (11.9) |
| Symptom duration, years | 19.9 (12.5) | 20.2 (13.4) | 19.5 (11.3) |
| EQ-5D (0–1)a | 0.66 (0.24) | 0.63 (0.26) | 0.70 (0.22) |
| BASDAI (0–10) | 4.0 (2.2) | 4.5 (2.1) | 3.3 (2.1) |
| BASFI (0–10) | 3.2 (2.5) | 3.8 (2.4) | 2.5 (2.3) |
| Pain (0–10) | 4.2 (2.4) | 4.7 (2.3) | 3.6 (2.5) |
| Fatigue (0–10) | 4.9 (2.7) | 5.5 (2.5) | 4.1 (2.7) |
| HADs, anxiety (0–21) | 5.5 (4.3) | 6.2 (4.6) | 4.7 (3.9) |
| HADs, depression (0–21) | 4.2 (3.6) | 4.5 (3.7) | 3.9 (3.4) |
| HEPA yes/no, n (%) | 343/402 (46/54) | 168/250 (40/60) | 175/152 (54/46) |
| BMI (kg/m2) | 27.1 (4.7) | 26.8 (5.0) | 27.4 (4.3) |
| Smoking no/stopped/yes, n (%) | 291/352/97 (39/47/13) | 147/193/77 (35/46/18) | 144/159/20 (44/49/6) |
| Snuff/snus no/stopped/yes, n (%) | 582/56/80 (78/8/11) | 371/4/21 (89/1/5) | 211/52/59 (65/16/18) |
| Age, years | 52.9 (12.9) | 52.6 (13.2) | 53.5 (12.3) |
| Symptom duration, years | 19.9 (12.3) | 19.5 (11.9) | 20.5 (13.0) |
| EQ-5D (0–1)a | 0.68 (0.24) | 0.67 (0.23) | 0.70 (0.25) |
| BASDAI (0–10) | 4.0 (2.3) | 4.3 (2.3) | 3.5 (2.3) |
| BASFI (0–10) | 2.9 (2.4) | 3.3 (2.4) | 2.3 (2.2) |
| Pain (0–10) | 4.1 (2.5) | 4.4 (2.6) | 3.7 (2.4) |
| Fatigue (0–10) | 4.9 (2.9) | 5.2 (2.8) | 4.3 (2.8) |
| HADs, anxiety (0–21) | 5.5 (4.5) | 5.7 (4.5) | 5.2 (4.5) |
| HADs, depression (0–21) | 4.1 (3.9) | 4.1 (3.9) | 4.1 (4.0) |
| HEPA yes/no, n (%) | 128/120 (52/48) | 78/77 (50/50) | 50/43 (54/46) |
| BMI (kg/m2) | 26.0 (4.5) | 26.0 (4.8) | 26.0 (4.1) |
| Smoking no/stopped/yes, n (%) | 137/83/28 (55/34/11) | 84/51/20 (54/33/13) | 53/32/8 (57/34/9) |
| Snuff/snus no/stopped/yes, n (%) | 211/8/22 (85/3/9) | 141/2/6 (91/1/4) | 70/7/16 (75/7/17) |
Values are mean (SD), unless otherwise indicated
SpA spondyloarthritis, AS ankylosing spondylitis, PsA psoriatic arthritis, USpA undifferentiated spondyloarthritis, EQ-5D EuroQoL 5-Dimensions, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, HADs Hospital Anxiety and Depression scale, HEPA health-enhancing physical activity, BMI body mass index
aUtilities calculated by the British time trade-off-based preference set. Missing data: symptom duration: 108 (8%), EQ-5D: 66 (5%), BASDAI: 31 (2%), BASFI: 24 (1.7%), Pain/Fatigue 5 (0.3%), HADs anxiety/depression: 9 (0.6%), Smoking: 5 (0.4%), Snuff: 40 (2.8%)
Differences in lifestyle factors for all SpA, stratified for SpA-subgroups and men and women
| SpA-subgroup | All | Women | Men | |
|---|---|---|---|---|
| HEPA yes/no, n (%) | 697/729 (49/51) | 320/428 (43/57) | 377/301 (56/44) | ≤ 0.001 |
| BMI below/above 25 kg/m2, n (%) | 565/861 (40/60) | 327/421 (44/56) | 238/440 (35/65) | 0.001 |
| Tobacco yes/no-stopped, n (%) | 299/1127 (21/79) | 146/602 (20/80) | 153/525 (23/77) | 0.158 |
| HEPA yes/no, n (%) | 226/207 (52/48) | 74/101 (42/58) | 152/106 (59/41) | 0.001 |
| BMI below/above 25 kg/m2, n (%) | 189/244 (44/56) | 90/85 (51/49) | 99/159 (38/62) | 0.007 |
| Tobacco yes/no-stopped, n (%) | 83/350 (19/81) | 26/149 (15/85) | 57/201 (22/78) | 0.061 |
| HEPA yes/no, n (%) | 343/402 (46/54) | 168/250 (40/60) | 175/152 (54/46) | ≤ 0.001 |
| BMI below/above 25 kg/m2, n (%) | 262/483 (35/65) | 168/250 (40/60) | 94/233 (29/71) | 0.001 |
| Tobacco yes/no-stopped, n (%) | 168/577 (23/77) | 95/323 (23/77) | 73/254 (22/78) | 0.896 |
| HEPA yes/no, n (%) | 128/120 (52/48) | 78/77 (50/50) | 50/43 (54/46) | 0.600 |
| BMI below/above 25 kg/m2, n (%) | 114/134 (46/54) | 69/86 (45/55) | 45/48 (48/52) | 0.554 |
| Tobacco yes/no-stopped, n (%) | 48/200 (19/81) | 25/130 (16/84) | 23/70 (25/75) | 0.097 |
Chi-squared tests were used for group comparisons of proportions for healthy/unhealthy lifestyle factors
SpA spondyloarthritis, AS ankylosing spondylitis, PsA psoriatic arthritis, USpA undifferentiated spondyloarthritis, HEPA health-enhancing physical activity, BMI body mass index
Fig. 1Bar charts showing proportions of number of unhealthy lifestyle factors (0–3) for SpA subgroups. SpA subgroups (AS, n = 433, PsA, n = 745, USpA, n = 248). Presented with error bars with 95% CI, p < 0.001, for all. AS ankylosing spondylitis, PsA psoriatic arthritis, USpA undifferentiated spondyloarthritis
Number of unhealthy lifestyle factors and associated factors in patients with SpA (n = 1426)
| No. unhealthy lifestyle factors | 0 | 1 | 2 | 3 | (95% CI) | |
|---|---|---|---|---|---|---|
| EQ-5D (0–1)a | 0.74 (0.19) | 0.69 (0.23) | 0.63 (0.27) | 0.59 (0.25) | − 0.06 (− 0.07; − 0.04) | ≤ 0.001 |
| BASDAI (0–10) | 2.9 (2.0) | 3.7 (2.2) | 4.4 (2.3) | 4.4 (2.0) | 0.61 (0.47; 0.74) | ≤ 0.001 |
| BASFI (0–10) | 2.0 (2.0) | 3.0 (2.5) | 3.7 (2.5) | 3.9 (2.5) | 0.67 (0.53; 0.82) | ≤ 0.001 |
| Pain (0–10) | 3.1 (2.2) | 4.0 (2.6) | 4.6 (2.7) | 4.6 (2.5) | 0.62 (0.46; 0.77) | ≤ 0.001 |
| Fatigue (0–10) | 3.6 (2.6) | 4.3 (2.6) | 4.9 (2.7) | 5.1 (2.5) | 0.60 (0.43; 0.76) | ≤ 0.001 |
| HADs anxiety (0–21) | 5.0 (4.1) | 5.1 (4.2) | 6.0 (4.5) | 6.7 (4.8) | 0.62 (0.35; 0.89) | ≤ 0.001 |
| HADs depression (0–21) | 3.4 (3.1) | 3.9 (3.4) | 4.7 (3.6) | 5.5 (4.5) | 0.71 (0.48; 0.93) | ≤ 0.001 |
Values presented as mean (SD). 0 = no unhealthy lifestyle factors. Analysis of covariance (ANCOVA) with beta-estimates (β-est) and 95% confidence intervals (CI), and adjustments for age and SpA subgroup
SpA spondyloarthritis, EQ-5D EuroQoL 5-dimensions, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, HADs Hospital Anxiety and Depression scale
aUtilities calculated by the British time trade-off-based preference set. Missing data: EQ-5D: 66 (5%), BASDAI: 31 (2%), BASFI: 24 (1.7%), Pain/Fatigue 5 (0.3%), HADs anxiety/depression: 9 (0.6%)
Results from logistic regression analyses for having ≥ 2 unhealthy lifestyle factors
| Independent variables | Dependent variable | |||
|---|---|---|---|---|
| ≥ 2 | < 2 | ≥ 2 unhealthy lifestyle factors | ||
| Unhealthy lifestyle factors | ||||
| Mean (SD) | OR 95% CI | |||
| Age, years | 58.6 (11.6) | 57.3 (14.0) | 1.01 (1.00;1.01) | 0.161 |
| SpA subgroup | ||||
| AS | 1 | |||
| PsA | 1.40 (1.10;1.78) | 0.007 | ||
| USpA | 0.96 (0.70;1.33) | 0.818 | ||
| EQ-5D (0–1)a | 0.62 (0.27) | 0.71 (0.22) | 0.25 (0.16;0.39) | ≤ 0.001 |
| BASDAI (0–10) | 4.4 (2.2) | 3.5 (2.1) | 1.21 (1.15;1.27) | ≤ 0.001 |
| BASFI (0–10) | 3.8 (2.5) | 2.7 (2.4) | 1.19 (1.14;1.25) | ≤ 0.001 |
| Pain (0–10) | 4.6 (2.5) | 3.7 (2.4) | 1.16 (1.11;1.22) | ≤ 0.001 |
| Fatigue (0–10) | 5.3 (2.7) | 4.4 (2.7) | 1.14 (1.10; 1.19) | ≤ 0.001 |
| HADs anxiety (0–21) | 6.1 (4.6) | 5.1 (4.1) | 1.06 (1.03;1.08) | ≤ 0.001 |
| HADs depression (0–21) | 4.8 (3.8) | 3.7 (3.3) | 1.09 (1.06;1.12) | ≤ 0.001 |
Presented with odds ratios (OR) and 95% CI. Age and SpA subgroup were included in all analyses, and all other variables were added separately, and adjusted for age and SpA subgroup. Number of patients included in analyses (range: n = 1426–1360)
SpA spondyloarthritis, AS ankylosing spondylitis, PsA psoriatic arthritis, USpA undifferentiated spondyloarthritis, EQ-5D EuroQoL 5-dimensions, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, HADs Hospital Anxiety and Depression scale
aUtilities calculated by the British time trade-off-based preference set. Missing data: EQ-5D: 66 (5%), BASDAI: 31 (2%), BASFI: 24 (1.7%), Pain/Fatigue 5 (0.3%), HADs anxiety/depression: 9 (0.6%)
Sub-analyses on patients with two unhealthy lifestyle factors. Results for not fulfilling HEPA recommendations
| Independent variables | Dependent variable | |||
|---|---|---|---|---|
| HEPA | No HEPA | No HEPA | ||
| Mean (SD) | OR 95% CI | |||
| Age, years | 55.5 (10.7) | 59.3 (12.0) | 1.03 (1.01;1.05) | 0.008 |
| SpA subgroup | ||||
| AS | 1 | |||
| PsA | 0.80 (0.45; 1.43) | 0.448 | ||
| USpA | 0.95 (0.43; 2.06) | 0.886 | ||
| EQ-5D (0–1)a | 0.67 (0.25) | 0.62 (0.28) | 0.47 (0.17;1.29) | 0.144 |
| BASDAI (0–10) | 3.9 (2.3) | 4.5 (2.2) | 1.13 (1.01;1.26) | 0.027 |
| BASFI (0–10) | 2.8 (2.4) | 3.9 (2.5) | 1.19 (1.06; 1.33) | 0.003 |
| Pain (0–10) | 4.1 (2.7) | 4.7 (2.5) | 1.09 (0.99; 1.20) | 0.084 |
| Fatigue (0–10) | 4.8 (3.0) | 5.4 (2.6) | 1.10 (1.01; 1.21) | 0.031 |
| HADs anxiety (0–21) | 5.8 (4.9) | 6.0 (4.5) | 1.02 (0.96; 1.08) | 0.544 |
| HADs depression (0–21) | 4.4 (4.2) | 4.7 (3.5) | 1.04 (0.97; 1.11) | 0.330 |
Logistic regression analyses presented with odds ratio (OR) and 95% CI. Age and SpA subgroup were included in all analyses, and all other variables were added separately and adjusted for age and SpA subgroup. Number of patients included in sub-analyses (range: n = 528–497)
HEPA health-enhancing physical activity, SpA spondyloarthritis, AS ankylosing spondylitis, PsA psoriatic arthritis, USpA undifferentiated spondyloarthritis, EQ-5D EuroQoL 5-dimensions, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, HADs Hospital Anxiety and Depression scale
aUtilities calculated by the British time trade-off-based preference set. Missing data: EQ-5D: 66 (5%), BASDAI: 31 (2%), BASFI: 24 (1.7%), Pain/Fatigue 5 (0.3%), HADs anxiety/depression: 9 (0.6%)